Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 14, 2024, titled "Zydus and ICMR initiate a Phase 2 proof-of-concept trial of Desidustat in patients with Sickle Cell Disease".
Press Release Oct 14 2024
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a press release regarding a new clinical trial. This initiative marks a significant step in developing new therapies for Sickle Cell Disease in India. The study aims to assess various health outcomes in patients receiving the treatment compared to a placebo.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 10 2024
- Press Release Oct 02 2024
- Press Release Oct 01 2024
- Press Release Sep 28 2024
- Press Release Sep 27 2024
Later from Zydus Lifesciences
- Press Release Oct 17 2024
- Press Release Oct 23 2024
- Press Release Nov 12 2024
- Press Release Dec 19 2024
- Zydus Lifesciences Limited Press Release Jan 07 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences